Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C56H92O29 |
Molecular Weight | 1229.3123 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 38 / 38 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12O[C@]3(CC[C@@H](C)CO3)[C@@H](C)[C@]1([H])[C@@]4(C)CC[C@@]5([H])[C@@]([H])(CC[C@@]6([H])C[C@@H](O[C@]7([H])O[C@H](CO)[C@H](O[C@]8([H])O[C@H](CO)[C@@H](O)[C@H](O[C@]9([H])OC[C@@H](O)[C@H](O)[C@H]9O)[C@H]8O[C@]%10([H])O[C@H](CO)[C@H](O)[C@H](O[C@]%11([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%11O)[C@H]%10O)[C@H](O)[C@H]7O)[C@H](O)C[C@]56C)[C@]4([H])[C@@H]2O
InChI
InChIKey=UVYVLBIGDKGWPX-KUAJCENISA-N
InChI=1S/C56H92O29/c1-19-7-10-56(75-17-19)20(2)31-45(85-56)37(67)32-22-6-5-21-11-26(24(61)12-55(21,4)23(22)8-9-54(31,32)3)76-50-42(72)39(69)44(30(16-60)80-50)81-53-48(47(36(66)29(15-59)79-53)83-49-40(70)33(63)25(62)18-74-49)84-52-43(73)46(35(65)28(14-58)78-52)82-51-41(71)38(68)34(64)27(13-57)77-51/h19-53,57-73H,5-18H2,1-4H3/t19-,20+,21+,22-,23+,24-,25-,26-,27-,28-,29-,30-,31+,32-,33+,34-,35+,36-,37+,38+,39-,40-,41-,42-,43-,44+,45-,46+,47+,48-,49+,50-,51+,52+,53+,54-,55+,56-/m1/s1
Digitonin is a steroidal saponin (saraponin) obtained from the foxglove plant Digitalis purpurea. As a non-ionic detergent Digitonin is commonly used to solubilize membrane-bound proteins. Digitonin forms a complex with its lipophilic terpenoid moiety with cholesterol in the biomembrane; additionally it binds to glycoproteins and glycolipids of the cell membrane with its sugar side chain. This leads to a severe tension of the biomembrane and influences membrane permeability. Digitonin, in combination with secondary metabolites, leads to a stronger inhibition of ABC transporters as when applied alone. Digitonin is used as a clinical reagent for the cholesterol determination. Digitonin mixed in the diet was well tolerated by rats and cynomolgus monkeys (Macaca fascicularis), and prevented the expected rise in plasma cholesterol in monkeys fed a diet containing butter and cholesterol.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4302 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23999162 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells. | 2011 Sep 30 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/417616
Macaca fascicularis: 0.4 g/100 g of food
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23999162
The accumulation of Rho123 and CAM was assessed in Caco-2 and CEM/ADR5000 cells after treatment with the set of secondary metabolites in combination with 5 uM digitonin. The intracellular accumulation of Rho123 and CAM was significantly enhanced in Caco-2 cells in a dose dependent manner. The synergistic effect of EGCG, thymol, beta-sitosterol-O-glucoside, and harmine, in combination with digitonin, represent the highest enhancement factor (between 1.45 and 1.98) and inhibitory activity of P-gp efflux (between 220% and 469%).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1025065
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
100000127482
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
DIGITONIN
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
234-255-6
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
m4450
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
27729
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
D004072
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
11024-24-1
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
23471
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
6474107
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
SUB33508
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY | |||
|
KOO5CM684H
Created by
admin on Fri Dec 15 15:50:10 GMT 2023 , Edited by admin on Fri Dec 15 15:50:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY